FADS3 Antibody

What is FADS3 and why are antibodies against it important for research?

FADS3 (Fatty Acid Desaturase 3) is a member of the fatty acid desaturase gene cluster that includes FADS1 and FADS2, sharing 62% and 70% nucleotide sequence identity with these genes, respectively . Unlike its well-characterized counterparts that function as Δ5- and Δ6-desaturases, FADS3 has been identified as a Δ14Z sphingoid base desaturase that contributes to the formation of sphingolipids with dienic long-chain bases .

Antibodies against FADS3 are crucial research tools because they allow for the detection and characterization of multiple FADS3 protein isoforms (75 kDa, 51 kDa, and 37 kDa) that are expressed in a tissue-dependent manner . These antibodies enable researchers to investigate FADS3's unique tissue distribution pattern, which differs from that of FADS1 and FADS2, and to study its potential roles in lipid metabolism and associated pathologies.

How many FADS3 protein isoforms exist and how are they distributed across tissues?

Research has identified three potential protein isoforms of FADS3 with molecular weights of 75 kDa, 51 kDa, and 37 kDa that are present in a tissue-dependent manner . The occurrence of these isoforms does not directly correlate with mRNA levels as determined by real-time PCR, suggesting post-transcriptional regulation mechanisms.

In rat tissues, FADS3 mRNAs are predominantly found in the lung, white adipose tissue, aorta, spleen, heart, and kidney, which differs significantly from the distribution pattern of FADS1 and FADS2 that show highest expression in liver, kidney, brain, lung, and aorta . Human tissue expression data from the GTEx portal indicates highest FADS3 expression in peripheral nerve, aorta, and adipose tissue, with most tissues showing higher expression in females than males (notably, adipose tissues show 194.6 TPM in females versus 166.7 TPM in males) .

The tissue-specific distribution of different FADS3 isoforms suggests distinct physiological roles that may vary between tissues and possibly between species.

What is the structural composition of FADS3 and how does it inform antibody design?

FADS3 is a membrane-bound desaturase composed of an N-terminal cytochrome b5-like domain and a C-terminal fatty acid desaturase domain . This structure is characteristic of front-end desaturases and includes three histidine motifs at the C-terminal end .

When designing antibodies against FADS3, researchers have successfully targeted specific peptide sequences at both the N-terminal (31QIRQHDLPGDKWL) and C-terminal (352PKEIGHEKHRDWAS) ends of the protein . These target peptides display varying degrees of conservation across species, with the C-terminal sequence showing 100% identity between rat and human proteins, while the N-terminal sequence shows 85% identity . This conservation information is critical when developing antibodies that can recognize FADS3 across different species.

The structural features of FADS3 inform not only antibody design but also provide insights into its cellular localization and function, as immunofluorescence microscopy has confirmed its presence in the endoplasmic reticulum through colocalization with calnexin .

How can researchers differentiate between FADS3 isoforms using antibody-based techniques?

Differentiating between FADS3 isoforms requires a strategic approach to antibody selection and experimental design. Researchers have successfully employed two specific polyclonal antibodies directed against the N-terminal and C-terminal ends of FADS3 (anti-NtermFADS3 and anti-CtermFADS3) to identify different isoforms . These antibodies can detect the three potential protein isoforms (75 kDa, 51 kDa, and 37 kDa) that are present in a tissue-dependent manner.

For optimal differentiation between isoforms, researchers should:

• Perform both SDS-PAGE and native PAGE Western blotting, as certain structural features may be preserved in native conditions that affect antibody recognition.

• Use both N-terminal and C-terminal targeted antibodies in parallel experiments to confirm isoform identity.

• Include appropriate molecular weight markers and known controls.

• Consider using anti-FADS2/3 antibodies that have cross-reactivity to provide additional confirmation.

The different banding patterns observed across tissues suggest that post-translational modifications or alternative splicing events may generate these isoforms, requiring careful validation through additional techniques such as mass spectrometry for definitive identification.

What are the experimental considerations when using FADS3 antibodies to study its enzymatic function as a Δ14Z sphingoid base desaturase?

When investigating FADS3's enzymatic function as a Δ14Z sphingoid base desaturase using antibody-based approaches, researchers should consider several critical factors:

• Substrate specificity: FADS3 can metabolize both free and N-acylated long-chain bases (LCBs) . Experimental designs should account for this dual substrate capability when assessing enzymatic activity.

• Subcellular localization: Since FADS3 localizes to the endoplasmic reticulum , fractionation procedures must preserve ER integrity before antibody-based detection.

• Activity assays: When correlating protein levels (detected via antibodies) with enzymatic activity, researchers should use isotope-labeled substrates such as (d7)d18:0 or (d3)m18:0 followed by LC-MS analysis of the resulting sphingolipid profiles .

• Inhibitor studies: The use of inhibitors like fumonisin B1 (FB1) in conjunction with antibody detection can help determine whether FADS3 acts on N-acylated or free LCBs .

• Controls: Expression systems comparing FADS3 with FADS1 and FADS2 are essential to demonstrate specificity, as studies have shown that only FADS3 overexpression increases d18:2 formation .

Researchers should also be aware that FADS3 expression responds inversely to FADS1 and FADS2 levels, with FADS3 expression increasing 3-fold in FADS2-deficient mice . This interrelationship may affect experimental interpretations when studying FADS3 in various genetic backgrounds.

How do sex differences in FADS3 expression impact experimental design and data interpretation?

Sex differences in FADS3 expression have significant implications for experimental design and data interpretation. Research has shown that the majority of tissues exhibit higher FADS3 expression in females compared to males, with particularly pronounced differences in adipose tissues (194.6 TPM in females versus 166.7 TPM in males) . These sex-dependent expression patterns correlate with observations that d18:2 plasma levels are higher in females .

To account for these differences, researchers should:

• Sex-stratify experimental groups and data analysis

• Ensure balanced sex representation in study designs

• Consider hormonal influences on FADS3 expression

• Report sex as a biological variable in all FADS3-related research

• Validate antibody performance in tissues from both sexes

When interpreting antibody-based detection data, researchers should consider that different antibody epitopes might be differentially accessible due to sex-specific post-translational modifications or protein-protein interactions. Additionally, the correlation between protein levels (detected by antibodies) and functional outcomes may vary between sexes.

This table summarizes key sex differences in FADS3 expression across tissues based on GTEx portal data:

What are the validated protocols for FADS3 antibody production and purification?

Validated protocols for producing high-specificity FADS3 antibodies involve several critical steps that have been demonstrated in the literature:

• Epitope selection: Successful FADS3 antibodies have been generated using specific peptides corresponding to the N-terminal sequence (31QIRQHDLPGDKWL) and the carboxyl-terminal sequence (352PKEIGHEKHRDWAS) of FADS3 . These regions show differential conservation across species, with the C-terminal peptide showing 100% identity between rat and human proteins.

• Immunization strategy: The double-X 28-day protocol has proven effective for FADS3 antibody production. This involves co-immunizing rabbits with both peptides coupled to Keyhole Limpet Hemocyanin (KLH) as a carrier protein over a 4-week period .

• Purification method: Affinity chromatography using the immunizing peptides as ligands is the recommended approach for purifying anti-FADS3 antibodies from serum . This yields highly specific antibodies referred to as anti-NtermFADS3 and anti-CtermFADS3.

• Validation steps: Successful FADS3 antibodies should be validated through:

  • Blotting against immunizing peptides

  • Western blotting against recombinant FADS3

  • Testing cross-reactivity with FADS1 and FADS2

  • Confirming tissue-specific detection patterns

For laboratories without resources to develop custom antibodies, an alternative approach is to use antibodies like anti-FADS2/3 that show immunospecificity with both recombinant FADS2 and FADS3 , though these may lack the specificity of targeted antibodies.

How should researchers optimize Western blotting conditions for detecting different FADS3 isoforms?

Optimizing Western blotting conditions for detecting different FADS3 isoforms requires careful attention to several technical parameters:

• Sample preparation:

  • For membrane proteins like FADS3, use appropriate detergents (e.g., NP-40, Triton X-100) for efficient extraction

  • Include protease inhibitors to prevent degradation of isoforms

  • Consider both reduced and non-reduced conditions, as disulfide bonds may affect epitope accessibility

• Gel selection:

  • Use both SDS-PAGE and native PAGE, as different isoforms may be better resolved under different conditions

  • For SDS-PAGE, gradient gels (4-15%) provide better separation of the three FADS3 isoforms (75 kDa, 51 kDa, and 37 kDa)

  • Include appropriate molecular weight markers to accurately determine isoform sizes

• Antibody selection and concentration:

  • Use purified antibodies at 1 μg/ml in tris-buffered saline (20 mM Tris-HCl, 150 mM NaCl; pH7.4) containing 0.05% Tween-20 and 5% BSA

  • Incubate primary antibodies overnight at 4°C for optimal binding

  • Compare results using both anti-NtermFADS3 and anti-CtermFADS3 to confirm isoform detection

• Detection system:

  • Use HRP-conjugated secondary antibodies and chemiluminescent detection with Immobilon reagents

  • Consider digital imaging systems for quantitative analysis of isoform expression

  • Include protein loading controls (actin or GAPDH), noting that certain tissues may not express these housekeeping proteins consistently

• Validation controls:

  • Include recombinant FADS3 as a positive control

  • Use tissues known to express specific isoforms based on previous research

  • Consider FADS3 knockdown or knockout samples as negative controls

What techniques can be combined with FADS3 antibody detection to fully characterize its enzymatic function?

A comprehensive characterization of FADS3's enzymatic function requires combining antibody detection with multiple complementary techniques:

• Expression systems and antibody detection:

  • Express mouse or human FADS3 cDNA in cell lines (e.g., HEK293)

  • Confirm expression levels via Western blotting using validated antibodies

  • Verify subcellular localization via immunofluorescence microscopy (colocalization with ER markers like calnexin)

• Enzyme activity assays:

  • Supplement cells with isotope-labeled substrates such as (d7)d18:0 or (d3)m18:0

  • Extract lipids and perform hydrolysis after 48 hours of incubation

  • Analyze long-chain base (LCB) profiles using LC-MS to detect conversion products

  • Compare results with FADS1 and FADS2 expressing cells as controls

• Substrate specificity determination:

  • Treat cells with fumonisin B1 (FB1) to inhibit ceramide synthase and prevent N-acylation of LCBs

  • Add either free LCBs (e.g., (d7)d18:1) or N-acylated forms (e.g., d18:1/6:0) to cell-free extracts from FADS3-expressing cells

  • Measure conversion to dienic forms to determine substrate preferences

• Genetic manipulation coupled with antibody detection:

  • Perform siRNA knockdown experiments in cells with high endogenous FADS3 expression (e.g., HeLa cells)

  • Confirm knockdown efficiency via Western blotting

  • Analyze changes in LCB profiles following knockdown to confirm enzyme function

  • Compare with FADS3-deficient mouse models

• Functional relevance testing:

  • Culture wild-type and FADS3-overexpressing cells with increasing amounts of potential substrates (e.g., m18:0)

  • Quantify surviving cells after 48h to assess potential protective effects

  • Correlate protection with FADS3 protein levels and activity

How can researchers address discrepancies between FADS3 mRNA levels and protein detection using antibodies?

Discrepancies between FADS3 mRNA levels and protein detection are common challenges in research, as studies have shown that the occurrence of FADS3 protein isoforms does not depend directly on the mRNA level determined by real-time PCR . To address these discrepancies, researchers should implement a systematic approach:

• Verify antibody specificity:

  • Confirm that the antibodies recognize recombinant FADS3 protein

  • Test antibodies against tissues from FADS3 knockout models as negative controls

  • Evaluate cross-reactivity with other FADS family proteins

• Consider post-transcriptional regulation:

  • Assess microRNA-mediated regulation of FADS3 translation

  • Investigate RNA-binding proteins that might affect FADS3 mRNA stability or translation efficiency

  • Examine alternative splicing events that could generate different protein isoforms

• Evaluate protein stability factors:

  • Measure protein half-life using cycloheximide chase experiments

  • Investigate ubiquitination or other post-translational modifications affecting protein turnover

  • Consider tissue-specific factors that might influence protein stability

• Improve detection methods:

  • Use multiple antibodies targeting different epitopes to ensure comprehensive detection

  • Optimize protein extraction protocols for membrane proteins

  • Consider more sensitive detection methods such as proximity ligation assay (PLA)

• Quantification approach:

  • Use digital imaging and appropriate software for accurate quantification

  • Normalize to multiple housekeeping proteins

  • Account for tissue-specific variations in housekeeping protein expression

By systematically addressing these factors, researchers can better understand the relationship between FADS3 mRNA and protein levels, leading to more accurate interpretations of experimental data.

What are the common artifacts in FADS3 antibody staining and how can they be minimized?

When working with FADS3 antibodies, researchers may encounter several common artifacts that can complicate data interpretation. Understanding these artifacts and implementing strategies to minimize them is essential for generating reliable results:

• Non-specific binding:

  • Cause: Insufficient blocking or high antibody concentration

  • Solution: Optimize blocking conditions using 5% BSA in tris-buffered saline with 0.05% Tween-20 and titrate antibody concentrations

  • Validation: Include peptide competition assays to confirm specificity

• Cross-reactivity with other FADS proteins:

  • Cause: Sequence homology between FADS family members

  • Solution: Use epitopes with minimal sequence similarity to FADS1 and FADS2

  • Validation: Test antibodies against recombinant FADS1, FADS2, and FADS3 proteins

• Variable detection of isoforms:

  • Cause: Epitope masking in certain isoforms or conformations

  • Solution: Use antibodies targeting different regions (N-terminal and C-terminal)

  • Validation: Compare detection patterns across multiple tissues known to express different isoforms

• Background in immunofluorescence:

  • Cause: ER localization causing diffuse staining patterns

  • Solution: Use confocal microscopy and co-staining with ER markers like calnexin

  • Validation: Include cells with FADS3 knockdown as negative controls

• Inconsistent detection across species:

  • Cause: Sequence variations between species

  • Solution: Verify epitope conservation (e.g., C-terminal epitope shows 100% identity between rat and human proteins)

  • Validation: Test antibodies against tissues from multiple species

• Protein degradation artifacts:

  • Cause: Proteolytic cleavage during sample preparation

  • Solution: Use freshly prepared samples with protease inhibitors

  • Validation: Compare different sample preparation methods to identify consistent banding patterns

By implementing these strategies, researchers can significantly reduce artifacts and generate more reliable and reproducible data when using FADS3 antibodies.

How should researchers interpret FADS3 antibody signals in relation to its enzymatic activity across different tissues?

Interpreting FADS3 antibody signals in relation to enzymatic activity requires a nuanced approach that accounts for several tissue-specific factors:

• Isoform-specific activity:

  • Different FADS3 isoforms (75 kDa, 51 kDa, and 37 kDa) may have varying enzymatic activities

  • Correlate the presence of specific isoforms detected by antibodies with enzymatic assays measuring conversion of d18:1 to d18:2 or m18:0 to m18:1

  • Consider that certain isoforms may be catalytically inactive but serve regulatory functions

• Subcellular localization variations:

  • While FADS3 generally localizes to the ER , tissue-specific variations in subcellular distribution may affect activity

  • Use immunofluorescence with organelle markers to determine if localization correlates with activity differences

  • Consider that membrane composition varies between tissues, potentially affecting enzyme orientation and access to substrates

• Co-expression with other pathway components:

  • The presence of substrate-generating or product-metabolizing enzymes may influence apparent FADS3 activity

  • Evaluate co-expression of ceramide synthases, sphingomyelinases, and other relevant enzymes in the same tissues

  • Consider that FADS3 expression responds inversely to FADS1 and FADS2 levels , potentially reflecting compensatory mechanisms

• Sex-specific considerations:

  • Given that FADS3 expression is generally higher in females than males , sex-stratified analysis is essential

  • Higher d18:2 plasma levels in females correlate with increased expression, suggesting functional relevance of sex differences

  • Hormone-dependent regulation may affect the relationship between protein levels and activity

• Interpretation framework:

  • Strong antibody signal without corresponding enzymatic activity may indicate post-translational regulation

  • Weak antibody signal with high enzymatic activity might suggest enhanced catalytic efficiency or rapid turnover

  • Tissue-specific correlation patterns may reveal regulatory mechanisms unique to certain physiological contexts

This integrated approach to interpretation provides a more comprehensive understanding of FADS3 biology than either antibody detection or activity assays alone could provide.

How are FADS3 antibodies being used to elucidate its role in lipid metabolism disorders?

FADS3 antibodies are increasingly instrumental in investigating connections between FADS3 function and lipid metabolism disorders:

• Genetic association validation:

  • FADS3 genetic variants have been associated with familial combined hyperlipidemia in the Mexican population, and the FADS3 SNP rs174455 shows negative associations with various phenotypes

  • Antibodies enable researchers to determine if these genetic variants affect protein expression, isoform distribution, or subcellular localization

  • Correlation between protein levels (detected by antibodies) and lipid profiles helps validate functional relevance of genetic associations

• Tissue-specific pathology investigation:

  • FADS3's unique tissue distribution, particularly its high expression in adipose tissue, peripheral nerve, and aorta , suggests tissue-specific roles in lipid metabolism

  • Antibody-based tissue profiling in metabolic disease models helps identify altered expression patterns that may contribute to pathology

  • Immunohistochemistry with FADS3 antibodies can reveal changes in cellular distribution during disease progression

• Sphingolipid metabolism in disease states:

  • FADS3's function as a Δ14Z sphingoid base desaturase links it to sphingolipid metabolism

  • Antibody-based detection combined with sphingolipidomic analysis helps correlate FADS3 levels with altered sphingolipid profiles in various disorders

  • This approach has revealed that FADS3 overexpression provides protection against m18:0 toxicity , suggesting therapeutic potential

• FADS cluster interactions:

  • The inverse relationship between FADS3 and FADS1/FADS2 expression indicates complex regulatory interactions within the FADS cluster

  • Antibodies against all three FADS proteins allow researchers to monitor these relationships in disease models

  • Such studies help determine whether disrupted FADS cluster regulation contributes to lipid metabolism disorders

• Interventional studies:

  • In research using high-fat diet models or metabolic challenge conditions, FADS3 antibodies enable monitoring of protein expression changes in response to interventions

  • This approach helps identify potential therapeutic strategies targeting FADS3 expression or activity

What emerging technologies are enhancing the utility of FADS3 antibodies in sphingolipid research?

Several cutting-edge technologies are significantly expanding the applications of FADS3 antibodies in sphingolipid research:

• Proximity labeling techniques:

  • BioID or APEX2 fusion with FADS3 combined with antibody-based detection allows mapping of the FADS3 interactome

  • This approach identifies novel protein-protein interactions that regulate FADS3 activity or localization

  • Reveals potential connections between FADS3 and other enzymes in sphingolipid metabolism pathways

• Super-resolution microscopy:

  • STORM or PALM imaging with FADS3 antibodies provides nanoscale resolution of its distribution within the ER

  • Enables visualization of potential subdomains where FADS3 concentrates, possibly in proximity to other sphingolipid-metabolizing enzymes

  • Helps determine if FADS3 associates with specialized membrane microdomains

• Live-cell imaging technologies:

  • Split-GFP or HaloTag approaches combined with antibody validation allow real-time monitoring of FADS3 dynamics

  • Reveals how FADS3 localization or interactions change in response to metabolic stimuli

  • Provides insights into the temporal regulation of FADS3 function

• Mass spectrometry imaging:

  • Correlation of FADS3 immunohistochemistry with MALDI-imaging of sphingolipids

  • Maps the spatial relationship between FADS3 protein levels and its products (d18:2-based sphingolipids)

  • Identifies tissue microdomains where FADS3 activity is particularly relevant

• CRISPR-based approaches:

  • CRISPR-Cas9 modification of endogenous FADS3 with epitope tags, validated against conventional antibodies

  • Enables more specific pull-down experiments for interactome studies

  • Allows precise manipulation of specific FADS3 domains to determine their role in enzymatic function

• Single-cell technologies:

  • Integration of antibody-based detection with single-cell transcriptomics

  • Reveals cell-type specific expression and regulation of FADS3 within heterogeneous tissues

  • Helps identify previously unrecognized cell populations where FADS3 plays critical roles

These technological advancements, when combined with traditional antibody applications, are providing unprecedented insights into FADS3 biology and its role in sphingolipid metabolism.

How might future developments in FADS3 antibody technology address current research limitations?

Future developments in FADS3 antibody technology hold significant promise for addressing several current research limitations:

• Isoform-specific antibodies:

  • Development of antibodies specifically targeting each of the three FADS3 isoforms (75 kDa, 51 kDa, and 37 kDa)

  • These would enable precise tracking of individual isoforms across tissues and conditions

  • Could reveal distinct functions or regulations for each isoform, currently a major knowledge gap

• Conformational antibodies:

  • Creation of antibodies that specifically recognize active versus inactive conformations of FADS3

  • Would enable direct assessment of enzyme activation state rather than just protein presence

  • Could help explain discrepancies between protein levels and enzymatic activity

• Post-translational modification-specific antibodies:

  • Development of antibodies recognizing specific phosphorylation, glycosylation, or other modifications of FADS3

  • Would reveal regulatory mechanisms controlling FADS3 activity

  • May identify targetable modification sites for therapeutic intervention

• Nanobodies and intrabodies:

  • Single-domain antibodies that can function in reducing environments

  • Would enable intracellular tracking of FADS3 in living cells

  • Could potentially modulate FADS3 function when expressed as intrabodies

• Bi-specific antibodies:

  • Antibodies recognizing both FADS3 and interacting proteins

  • Would enable detection of specific protein complexes relevant to FADS3 function

  • Could reveal how protein-protein interactions regulate FADS3 activity

• Humanized antibodies for in vivo studies:

  • Development of humanized anti-FADS3 antibodies suitable for in vivo administration

  • Would enable pharmacological modulation of FADS3 in animal models

  • Could provide proof-of-concept for FADS3-targeting therapeutic approaches

• Antibody-enzyme conjugates:

  • Coupling anti-FADS3 antibodies with enzymes that generate fluorescent or bioluminescent signals in proximity to substrates

  • Would enable real-time monitoring of FADS3 localization and activity

  • Could revolutionize our understanding of FADS3 dynamics in living systems

These anticipated developments would address current limitations in distinguishing between isoforms, correlating protein presence with activity, and understanding the dynamic regulation of FADS3 in living systems.